A 40-month median PFS — and counting.
In this clip, Drs. Mouabbi, O’Shaughnessy, and Rimawi break down DESTINY-Breast 09 and why moving T-DXd to the frontline may be one of the biggest breakthroughs yet in HER2+ metastatic breast cancer.
40-Month PFS: Can T-DXd Move to the Frontline?
You may also like
Recommended Videos
